Opendata, web and dolomites

Hemstem SIGNED

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Total Cost €


EC-Contrib. €






 Hemstem project word cloud

Explore the words cloud of the Hemstem project. It provides you a very rough idea of what is the project "Hemstem" about.

treatments    shift    leukemia    allogeneic    cell    leukemic    zebrafish    molecular    resistance    regulates    homing    costly    natural    hematopoiesis    hscs    vivo    advantages    conserved    severe    expansion    similarity    clinical    therapy    marrow    hematopoietic    self    simultaneously    affinity    curative    prove    despite    renewal    competitors    experimental    devastating    patients    inborn    intensity    insights    instead    malignant    immunotherapy    paradigm    lecular    small    surviving    decades    immune    wnt    interactions    signaling    modify    displace    mo    molecules    crude    bone    inhibit    acute    treatment    niches    lsc    fact    screens    transplantation    niche    diagnosis    ways    hsc    healthy    chemotherapy    lscs    myeloid    aml    profiling    stemness    patient    revolutionize    uses    surveillance    supporting    evolutionary    governing    mutations    eradicating    survive    subpopulations    30    wealth    strategies    explores    disease    home    difficult    mutational    human    stem    unable    bm    im    oncogenic    cells    visualize    protective    rationale   

Project "Hemstem" data sheet

The following table provides information about the project.


Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙984˙240 €
 EC max contribution 1˙984˙240 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 1˙984˙240.00


 Project objective

Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects. One reason why the wealth of molecular and experimental knowledge has so far been unable to revolutionize treatments is the fact that AML is driven by small subpopulations of so-called leukemic stem cells (LSCs), which survive chemotherapy and immune surveillance. LSCs have growth advantages induced by oncogenic mutations, but are in many ways similar to healthy hematopoietic stem cells (HSCs). This similarity makes it difficult to target LSCs without simultaneously eradicating HSCs and healthy hematopoiesis derived from these cells. Like HSCs, LSCs home to protective bone marrow (BM) niches promoting stemness and therapy resistance and modify them to displace HSCs and promote their own expansion. This proposal explores strategies to target LSCs based on understanding these interactions. In Aim 1 we investigate how WNT signaling, an evolutionary conserved pathway governing stem cell self-renewal, regulates interactions between leukemic and healthy hematopoietic (stem) cells. In Aim 2, we propose to inhibit the in vivo expansion of LSCs by enhancing self-renewal and niche affinity in their natural competitors, the healthy stem cells with inborn BM homing ability. Aim 3 uses zebrafish to visualize LSC-HSC interactions and screens for molecules supporting healthy instead of (pre-) malignant hematopoiesis. Our studies will im-prove the knowledge on the complex interactions between LSCs and HSCs and provide a rationale for novel treatments that might lead to a paradigm-shift in the clinical management of AML.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  
lastchecktime (2022-08-19 20:03:23) correctly updated